Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $2.92 down -1.02% from its previous closing price of $2.95. In other words, the price has decreased by -$1.02 from its previous closing price. On the day, 15.71 million shares were traded. IOVA stock price reached its highest trading level at $3.05 during the session, while it also had its lowest trading level at $2.78.
Ratios:
For a deeper understanding of Iovance Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 4.18. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 975087360 and an Enterprise Value of 669096384. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.58 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 3.146 whereas that against EBITDA is -1.833.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.94, which has changed by -0.6655212 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is 39.99%, while the 200-Day Moving Average is calculated to be -44.12%.
Shares Statistics:
For the past three months, IOVA has traded an average of 18.25M shares per day and 35276270 over the past ten days. A total of 333.93M shares are outstanding, with a floating share count of 271.39M. Insiders hold about 18.73% of the company’s shares, while institutions hold 64.34% stake in the company. Shares short for IOVA as of 1752537600 were 98633209 with a Short Ratio of 5.41, compared to 1749772800 on 90964131. Therefore, it implies a Short% of Shares Outstanding of 98633209 and a Short% of Float of 32.349998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
